Sam Mbulaiteye

Sam Mbulaiteye
Alma materMakerere University
University of Cambridge
Scientific career
FieldsCancer epidemiology
WorkplacesNational Cancer Institute

Sam Mbulaiteye (born in 1961) also known as Sam M. Mbulaiteye is a Ugandan physician-scientist and epidemiologist who researches Burkitt lymphoma. He is a senior investigator at the National Cancer Institute.[1] He conducts population studies and uses molecular and proteomic methods to search for risk factors that may be targeted to prevent or identify cancer at early stages.[1]

Early life and education

Sam Mbulaiteye was born in 1961. He completed his advanced secondary education (UACE) at St. Mary's College Kisubi (SMACK) between 1982 and 1985.[2]

Mbulaiteye went to Makerere University where he was trained as a physician in 1990 then joined University of Cambridge, U.K for an advanced training in epidemiology and biostatistics (M.Phil.)in 1994. After there, he was enrolled back at Makerere University for a specialist training in internal medicine (M.Med.).[3][2][4]

Career

Current roles and leadership (2025)

  • Senior Investigator. Lead researcher in the Infections and Immunoepidemiology Branch (IIB) of the NCI's Division of Cancer Epidemiology and Genetics (DCEG).
  • Principal Investigator. Heads the EMBLEM Study, a large case-control study investigating the multifactorial causes of Burkitt lymphoma (BL) across Uganda, Tanzania, and Kenya.
  • Editor-in-Chief. Serves as Co-Editor-in-Chief of the journal Infectious Agents and Cancer.
  • Committee Work. Active member of the DCEG Genotyping Review Committee.[5]

Key scientific contributions

  • Burkitt Lymphoma Research: His current work uses genomic methods, including Genome-Wide Association Studies (GWAS), to investigate how repeated malaria infections and the Epstein-Barr virus (EBV) interact to cause BL.
  • HIV/AIDS and Cancer: He was the first to use record-linkage methods to study the association between HIV and cancer in low- and middle-income countries, starting in Uganda in 2005.
  • Global Oncology: He provided early evidence showing declining HIV incidence in Uganda and identified the risk of Kaposi sarcoma-associated herpesvirus (KSHV) transmission via blood transfusions in Africa.[6]

Career timeline

He also holds membership in the Darwin College Society at the University of Cambridge.

Honours

  • DCEG Outstanding Mentor Award (2025). Recognized by the Division of Cancer Epidemiology and Genetics (DCEG) for his exceptional dedication to training and supporting junior scientists.[8]
  • Scientist of the Year (2022). Awarded by the Lymphoma Foundation of America for his leadership of the EMBLEM Study and his impactful work on the causes of childhood cancer in Africa.[9]
  • IARC/WHO Expert Contributor (2021). Invited by the International Agency for Research on Cancer to help update the WHO Classification of Tumours chapter on Burkitt lymphoma.[10]
  • NIH Scientific Tenure (2013). Formally awarded tenure by the National Institutes of Health (NIH) upon his appointment as a Senior Investigator.
  • NCI Director’s Innovation Award. Received this internal award to support his research on the relationship between malaria and cancer risk.[11]

See also

References

  1. ^ a b "Sam MBULAITEYE | Senior Investigator | MBChB, MPhil, MMed | National Cancer Institute (USA), Bethesda | NCI | Division of Cancer Epidemiology and Genetics | Research profile". ResearchGate. Archived from the original on 2023-01-20. Retrieved 2025-12-16.
  2. ^ a b "Sam Mbulaiteye, MBChB, M.Phil., M.Med., biographical sketch and research interests - NCI". dceg.cancer.gov. 1980-01-01. Retrieved 2025-12-17.
  3. ^ "Sam Mbulaiteye, MBChB, M.Phil., M.Med., biographical sketch and research interests - NCI". dceg.cancer.gov. 1980-01-01. Retrieved 2022-10-25.Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ "Sam Mbulaiteye, M.D. - Foundation for Burkitt Lymphoma". www.foundationforburkittlymphoma.org. Retrieved 2025-12-17.
  5. ^ "Sam M. Mbulaiteye, MBChB, M.Phil., M.Med. | Principal Investigators | NIH Intramural Research Program". irp.nih.gov. Retrieved 2025-12-17.
  6. ^ "Sam Mbulaiteye, M.D. - Foundation for Burkitt Lymphoma". www.foundationforburkittlymphoma.org. Retrieved 2025-12-17.
  7. ^ "Infectious Agents and Cancer". SpringerLink. Retrieved 2025-12-17.
  8. ^ "Infections and Immunoepidemiology Branch in DCEG - NCI". dceg.cancer.gov. 1980-01-01. Retrieved 2025-12-16.
  9. ^ "Epidemiology of Burkitt Lymphoma in East African Children and Minors (EMBLEM) in sub-Saharan Africa - NCI". dceg.cancer.gov. 2012-05-17. Retrieved 2025-12-16.
  10. ^ "Lymphoma Foundation of America- lymphomahelp.org". lymphomahelp.org. Retrieved 2025-12-16.
  11. ^ "Burkitt Lymphoma - Overview of BL research - NCI". dceg.cancer.gov. 2021-04-28. Retrieved 2025-12-16.
Public Domain This article incorporates public domain material from websites or documents of the National Institutes of Health.


Stub icon 1 Stub icon 2

This Ugandan biographical article related to medicine is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.